Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

出版年份 2021 全文链接

标题

作者

关键词

出版物

Volume 39, Issue 15_suppl, Pages 8511-8511

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2021-06-02

DOI

10.1200/jco.2021.39.15_suppl.8511

Explore over 38,000 international journals covering a vast array of academic fields.

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now